Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer

Exclusion Criteria

• •Subjects who have received chemotherapy for ovarian cancer other than debulking surgery.
• •Subjects who have a history of radiotherapy to pelvis or abdominal cavity
• •Subjects who receive immunotherapy or hormonal therapy for ovarian cancer
• •Subjects who have other malignancies within the past 5 years
• •Subjects who have had a major surgery other than debulking surgery within 2 weeks prior to the screening/baseline visit
• •Subjects who have a history of metastasis or currently have a metastasis to the central nervous system(CNS)
• •Subjects who have a preexisting sensory or motor neuropathy of grade ≥ 1 based on NCI CTCAE V3.0
• •Subjects who have serious medical condition
• •* Uncontrolled or severe cardiovascular disease(Ischemic heart disease, myocardial infarction within the last 6 months, congestive heart failure)
• •* Uncontrollable infection
• •* Previous allergic reactions in connection with paclitaxel and carboplatin
• •Subjects who participate another clinical trial within the last 4 weeks before inclusion